23:39 , Aug 2, 2017 |  BC Extra  |  Preclinical News

CDCP1 identified as potential autoimmune target

In a paper published in Proceedings of the National Academy of Sciences, researchers linked CUB domain containing protein 1 (CDCP1; CD318) to inflammatory arthritis and showed that knockout of the protein protected mice from autoimmune...
19:07 , Feb 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting CD6 could help treat MS. In an experimental autoimmune encephalomyelitis (EAE) mouse model of MS, CD6 knockout decreased clinical signs of encephalomyelitis and T cell infiltration in the...
08:00 , Nov 12, 2015 |  BC Innovations  |  Product R&D

Probodies, anticancer

Lauren Martz, Senior Writer  How successful checkpoint inhibitors and chimeric antigen receptor (CAR) T cells will be at revolutionizing oncology hangs largely on whether it will be possible to curb their on-target but off-tissue toxicities. CytomX...
07:00 , Apr 16, 2015 |  BC Innovations  |  Product R&D

Antagonizing psoriasis

Despite the heavy competition in psoriasis, AnaptysBio Inc. believes it can make a mark with a first-in-class antibody for a neglected, inherited form of pustular psoriasis caused by a loss-of-function mutation in the proinflammatory cytokine...
07:00 , Sep 16, 2013 |  BioCentury  |  Strategy

Alzumab's (re)mission statement

Biocon Ltd. is betting the long remission time and reduced opportunistic infections associated with its Alzumab itolizumab will pull doctors away from biologics with better efficacy in psoriasis. The company has long maintained that the first-in-class...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Biocon sales and marketing update

Biocon launched Alzumab itolizumab in India to treat chronic plaque psoriasis. Biocon said the price for a 25 mg/5 mL vial of Alzumab is Rs7,950 ($131) and that the recommended dose is 1.6 mg/kg,...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Alzumab itolizumab regulatory update

Biocon said India's Drugs Controller General of India (DCGI) approved Alzumab itolizumab to treat chronic plaque psoriasis. The company plans to launch the humanized IgG1 mAb that inhibits CD6 in the country later this...
01:24 , Jan 9, 2013 |  BC Extra  |  Company News

India approves Biocon's anti-CD6 mAb

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said India's Drugs Controller General of India (DCGI) approved Alzumab itolizumab to treat chronic plaque psoriasis. The company plans to launch the humanized IgG1 mAb that inhibits CD6 in the country...
08:00 , Jan 23, 2012 |  BioCentury  |  Product Development

Biocon's MOA bet

Though a Phase III trial of Biocon Ltd.'s anti-CD6 mAb itolizumab did not show as much efficacy as other biologics in psoriasis, the biotech thinks lower infection rates could differentiate the mAb from the anti-TNFs. Biocon...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

Itolizumab: Interim Phase III data

Interim data from the double-blind, placebo-controlled, Indian Phase III TREAT-PLAQ trial in 225 patients with moderate to severe plaque psoriasis showed that 0.4 and 1.6 mg/kg IV itolizumab every 2 weeks for 12 weeks met...